Treatment options applied to the preclinical studies using animal models for Chagas Disease: a systematic review and meta-analysis DOI Creative Commons
Laura Yesenia Machaca-Luque, Mayron Antonio Candia-Puma, Brychs Milagros Roque-Pumahuanca

et al.

F1000Research, Journal Year: 2025, Volume and Issue: 13, P. 885 - 885

Published: May 16, 2025

Background Chagas disease (CD) is a neglected tropical endemic to Latin America, has emerged as global health concern due the migration of infected individuals. With its epidemiological complexity, by difficulty obtain appropriate diagnoses and poor treatment, search for novel therapeutic options remains. Methods In this context, we conducted systematic review meta-analysis preclinical studies employing animal models verify progress in CD treatment. We searched PubMed database treatment published between 1990 2023, adhering PRISMA guidelines. Results Twelve papers met inclusion criteria. The findings indicate that fifteen alternatives examined, mainly 2010 2014, demonstrated efficacy experimental models, evidenced significant parasitemia reduction. Bis-triazole DO870 VNI were effective acute chronic phases, respectively. However, these emerging therapies, only posaconazole fexinidazole have progressed clinical trials, yielding unsatisfactory outcomes monotherapies Conclusions This highlights existence promising new drug candidates but most remain stages. Those reached trials did not demonstrate optimal results, underscoring ongoing challenges therapy. Collaborative efforts among academic community, pharmaceutical industries, funding agencies, government agencies are urgently needed accelerate development more medications against CD. Inplasy registration INPLASY202430101 (25/03/2024)

Language: Английский

Treatment options applied to the preclinical studies using animal models for Chagas Disease: a systematic review and meta-analysis DOI Creative Commons
Laura Yesenia Machaca-Luque, Mayron Antonio Candia-Puma, Brychs Milagros Roque-Pumahuanca

et al.

F1000Research, Journal Year: 2025, Volume and Issue: 13, P. 885 - 885

Published: April 15, 2025

Background Chagas disease (CD) is a neglected tropical endemic to Latin America, has emerged as global health concern due the migration of infected individuals. With its epidemiological complexity, by difficulty obtain appropriate diagnoses and poor treatment, search for novel therapeutic options remains. Methods In this context, we conducted systematic review meta-analysis preclinical studies employing animal models verify progress in CD treatment. We searched PubMed database treatment published between 1990 2023, adhering PRISMA guidelines. Results Twelve papers met inclusion criteria. The findings indicate that fifteen alternatives examined, mainly 2010 2014, demonstrated efficacy experimental models, evidenced significant parasitemia reduction. Bis-triazole DO870 VNI were effective acute chronic phases, respectively. However, these emerging therapies, only posaconazole fexinidazole have progressed clinical trials, yielding unsatisfactory outcomes monotherapies Conclusions This highlights existence promising new drug candidates but most remain stages. Those reached trials did not demonstrate optimal results, underscoring ongoing challenges therapy. Collaborative efforts among academic community, pharmaceutical industries, funding agencies, government agencies are urgently needed accelerate development more medications against CD. Inplasy registration INPLASY202430101 (25/03/2024)

Language: Английский

Citations

0
Treatment options applied to the preclinical studies using animal models for Chagas Disease: a systematic review and meta-analysis DOI Creative Commons
Laura Yesenia Machaca-Luque, Mayron Antonio Candia-Puma, Brychs Milagros Roque-Pumahuanca

et al.

F1000Research, Journal Year: 2025, Volume and Issue: 13, P. 885 - 885

Published: May 16, 2025

Background Chagas disease (CD) is a neglected tropical endemic to Latin America, has emerged as global health concern due the migration of infected individuals. With its epidemiological complexity, by difficulty obtain appropriate diagnoses and poor treatment, search for novel therapeutic options remains. Methods In this context, we conducted systematic review meta-analysis preclinical studies employing animal models verify progress in CD treatment. We searched PubMed database treatment published between 1990 2023, adhering PRISMA guidelines. Results Twelve papers met inclusion criteria. The findings indicate that fifteen alternatives examined, mainly 2010 2014, demonstrated efficacy experimental models, evidenced significant parasitemia reduction. Bis-triazole DO870 VNI were effective acute chronic phases, respectively. However, these emerging therapies, only posaconazole fexinidazole have progressed clinical trials, yielding unsatisfactory outcomes monotherapies Conclusions This highlights existence promising new drug candidates but most remain stages. Those reached trials did not demonstrate optimal results, underscoring ongoing challenges therapy. Collaborative efforts among academic community, pharmaceutical industries, funding agencies, government agencies are urgently needed accelerate development more medications against CD. Inplasy registration INPLASY202430101 (25/03/2024)

Language: Английский

Citations

0